TA-HPV

AXP000190.1 · Cancer vaccine

Platform
vaccinia virus
Originator
Cantab Pharmaceuticals

Names

NameTypeSource
TA-HPVpreferred name, codecurator, ncit
Human Papillomavirus Tumor Antigen Vaccinesynonymncit

Virus

Role
Vaccine vector
Family
Poxviridae
Virus
vaccinia virus (NCBI Taxonomy 10245)
Replication
replicating
Modifications
HPV-16 and HPV-18 E6/E7 cassettes inserted into vaccinia
Transgenes
HPV-16 E6, HPV-16 E7, HPV-18 E6, HPV-18 E7
Source
evidence

Cross-references

NCI Thesaurus
C2403

Approvals

No regulatory approval recorded.

Clinical trials (4)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT06315257A Clinical Trial to Assess PVX7 Immunotherapy Regimens in Advanced Cervical Cancer PatientsRecruitingPhase 12025-07-232029-0632Cervical Cancer
NCT06508138Clinical Trial Assessing the Safety and Immunologic Correlates of Heterologous Prime-Boost With pNGVL4a-Sig/E7(Detox)/HSP70 and TA-HPV in Healthy Donors Followed by Peripheral Blood CollectionEnrolling by invitationPhase 12023-10-182027-04-1824HPV 16 Infection; HPV-Related Carcinoma; Metastatic Cancer; Recurrence
NCT05799144pBI-11 & TA-HPV (With Pembrolizumab as Treatment for Patients w/Advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal CancerRecruitingPhase 22023-07-262027-09-3054Metastatic Oropharyngeal Carcinoma; Recurrent Oropharyngeal Carcinoma
NCT00788164Vaccine Therapy With or Without Imiquimod in Treating Patients With Grade 3 Cervical Intraepithelial NeoplasiaCompletedPhase 12008-112023-0875Cervical Cancer; HPV Disease; Human Papilomavirus; Precancerous Condition

Recent changes

No changes recorded in its trials yet.

Clinical papers

PubMedTitleJournalYearLinked by
PMID 33468698Development of DNA Vaccine Targeting E6 and E7 Proteins of Human Papillomavirus 16 (HPV16) and HPV18 for Immunotherapy in Combination with Recombinant Vaccinia Boost and PD-1 Antibody.mBio2021cited by trial NCT00788164
PMID 26420854Local HPV Recombinant Vaccinia Boost Following Priming with an HPV DNA Vaccine Enhances Local HPV-Specific CD8+ T-cell-Mediated Tumor Control in the Genital Tract.Clinical cancer research : an official journal of the American Association for Cancer Research2016cited by trial NCT00788164
PMID 24477000Intramuscular therapeutic vaccination targeting HPV16 induces T cell responses that localize in mucosal lesions.Science translational medicine2014cited by trial NCT00788164
PMID 16803488Prime-boost vaccination strategy in women with high-grade, noncervical anogenital intraepithelial neoplasia: clinical results from a multicenter phase II trial.International journal of gynecological cancer : official journal of the International Gynecological Cancer Society2006name in abstract: TA-HPV
PMID 15246603Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7).Vaccine2004name in title: TA-HPV
PMID 14614000Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia.Clinical cancer research : an official journal of the American Association for Cancer Research2003name in abstract: TA-HPV
PMID 8684105A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer.Lancet (London, England)1996name in abstract: TA-HPV

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 30296681Epithelial boost enhances antigen expression by vaccinia virus for the generation of potent CD8+ T cell-mediated antitumor immunity following DNA priming vaccination.Virology2018name in abstract: TA-HPV
PMID 23615841Intratumoral injection of therapeutic HPV vaccinia vaccine following cisplatin enhances HPV-specific antitumor effects.Cancer immunology, immunotherapy : CII2013name in abstract: TA-HPV
PMID 20886392TA-CIN, a vaccine incorporating a recombinant HPV fusion protein (HPV16 L2E6E7) for the potential treatment of HPV16-associated genital diseases.Current opinion in molecular therapeutics2010name in abstract: TA-HPV
PMID 15623547Epitope specificity and longevity of a vaccine-induced human T cell response against HPV18.International immunology2005name in abstract: TA-HPV
PMID 14522932Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins.Cancer research2003name in abstract: TA-HPV
PMID 12473576Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer.Clinical cancer research : an official journal of the American Association for Cancer Research2002name in title: TA-HPV
PMID 11257391Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer.Vaccine2001name in abstract: TA-HPV
PMID 11395199Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens.Vaccine2001name in abstract: TA-HPV
PMID 11804273Technology evaluation: T-cell activator, Xenova.Current opinion in molecular therapeutics2001name in abstract: TA-HPV
PMID 9014288Construction and characterisation of a recombinant vaccinia virus expressing human papillomavirus proteins for immunotherapy of cervical cancer.Vaccine1996name in abstract: TA-HPV

NIH grants

ProjectTitleOrganisationPIYearsLinked by
P50CA098252Therapeutic HPV vaccines (PVX7) for Advanced Cervical CancerJOHNS HOPKINS UNIVERSITYWU, TZYY-CHOOU2014–2026name in abstract: TA-HPV
R01CA142691Mechanisms of mucosal immune evasion in high grade cervical dysplasiaJOHNS HOPKINS UNIVERSITYTRIMBLE, CORNELIA L2010–2014name in abstract: TA-HPV
R43CA174436Therapeutic vaccination against genital HPV infectionPAPIVAX, LLCCHANG, YUNG-NIEN2013–2013name in abstract: TA-HPV
Z01SC010075A PHASE I/II STUDY OF A VACCINIA-HPV RECOMBINANTDIVISION OF CLINICAL SCIENCES - NCIKHLEIF, SAMIR1996–2000name in abstract: TA-HPV

Notes

Recombinant vaccinia virus encoding HPV-16 and HPV-18 E6 and E7; used in therapeutic trials for cervical and vulval intraepithelial neoplasia since the 1990s and still used as a boost after DNA priming (e.g. the PVX7/pBI-11 regimen, NCIt C212077). Vaccinia strain (Wyeth) and the Cantab/Xenova originator attribution were not verified from a primary source in this pass; replication competence recorded as replicating on that basis and should be checked.

How to cite

TA-HPV (AXP000190.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000190.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.